Laurus Labs Limited received FDA approval on October 5, 2023, for its generic product under application number ANDA217631, signaling a significant expansion of supply for the oral antidiabetic Metformin Hydrochloride. This approval is poised to deepen Laurus Labs' participation in the glucose management market, providing a cost-effective alternative to branded therapies and leveraging ongoing commoditization trends within the diabetes sector.